test_run_metadata:
  timestamp: '2025-06-04T20:44:21.798126'
  total_test_suites: 2
  python_version: 3.10.9 (main, Mar  1 2023, 12:20:14) [Clang 14.0.6 ]
  working_directory: /Users/robertlee/Desktop/ws/bloodCancerClassify/tests
  extraction_method: programmatic_parametrize_parsing
test_suites:
  aml_classification:
    test_suite: AML Classification
    timestamp: '2025-06-04T20:44:21.798163'
    total_tests: 102
    test_cases:
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[0]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 25.0
        AML_defining_recurrent_genetic_abnormalities:
          PML::RARA: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: Acute promyelocytic leukaemia with PML::RARA fusion (WHO 2022)
        actual: Acute promyelocytic leukaemia with PML::RARA fusion (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: PML::RARA'
        - PML::RARA => Acute promyelocytic leukaemia with PML::RARA fusion
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute promyelocytic leukaemia with PML::RARA fusion
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[1]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 30.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
          PML::RARA: false
        qualifiers: {}
      who_2022:
        expected: AML with NPM1 mutation (WHO 2022)
        actual: AML with NPM1 mutation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: NPM1'
        - NPM1 => AML with NPM1 mutation
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with NPM1 mutation (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[2]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 35.0
        AML_defining_recurrent_genetic_abnormalities:
          RUNX1::RUNX1T1: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with RUNX1::RUNX1T1 fusion (WHO 2022)
        actual: AML with RUNX1::RUNX1T1 fusion (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 35.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: RUNX1::RUNX1T1'
        - RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with RUNX1::RUNX1T1 fusion (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[3]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 40.0
        AML_defining_recurrent_genetic_abnormalities:
          CBFB::MYH11: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with CBFB::MYH11 fusion (WHO 2022)
        actual: AML with CBFB::MYH11 fusion (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 40.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: CBFB::MYH11'
        - CBFB::MYH11 => AML with CBFB::MYH11 fusion
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with CBFB::MYH11 fusion (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[4]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 45.0
        AML_defining_recurrent_genetic_abnormalities:
          DEK::NUP214: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with DEK::NUP214 fusion (WHO 2022)
        actual: AML with DEK::NUP214 fusion (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 45.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: DEK::NUP214'
        - DEK::NUP214 => AML with DEK::NUP214 fusion
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with DEK::NUP214 fusion (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[5]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 50.0
        AML_defining_recurrent_genetic_abnormalities:
          RBM15::MRTFA: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with RBM15::MRTFA fusion (WHO 2022)
        actual: AML with RBM15::MRTFA fusion (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 50.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: RBM15::MRTFA'
        - RBM15::MRTFA => AML with RBM15::MRTFA fusion
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with RBM15::MRTFA fusion (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[6]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 28.0
        AML_defining_recurrent_genetic_abnormalities:
          MLLT3::KMT2A: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with KMT2A rearrangement (WHO 2022)
        actual: AML with KMT2A rearrangement (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 28.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: MLLT3::KMT2A'
        - MLLT3::KMT2A => AML with KMT2A rearrangement
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with KMT2A rearrangement (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[7]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 33.0
        AML_defining_recurrent_genetic_abnormalities:
          'GATA2:: MECOM': true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with MECOM rearrangement (WHO 2022)
        actual: AML with MECOM rearrangement (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 33.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: GATA2:: MECOM'
        - 'GATA2:: MECOM => AML with MECOM rearrangement'
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with MECOM rearrangement (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[8]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 38.0
        AML_defining_recurrent_genetic_abnormalities:
          KMT2A: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with KMT2A rearrangement (WHO 2022)
        actual: AML with KMT2A rearrangement (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 38.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: KMT2A'
        - KMT2A => AML with KMT2A rearrangement
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with KMT2A rearrangement (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[9]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 42.0
        AML_defining_recurrent_genetic_abnormalities:
          MECOM: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with MECOM rearrangement (WHO 2022)
        actual: AML with MECOM rearrangement (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 42.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: MECOM'
        - MECOM => AML with MECOM rearrangement
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with MECOM rearrangement (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[10]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 26.0
        AML_defining_recurrent_genetic_abnormalities:
          NUP98: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with NUP98 rearrangement (WHO 2022)
        actual: AML with NUP98 rearrangement (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 26.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: NUP98'
        - NUP98 => AML with NUP98 rearrangement
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with NUP98 rearrangement (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[11]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 22.0
        AML_defining_recurrent_genetic_abnormalities:
          CEBPA: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with CEBPA mutation (WHO 2022)
        actual: AML with CEBPA mutation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 22.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: CEBPA'
        - CEBPA with blasts >=20 => AML with CEBPA mutation
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with CEBPA mutation (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[12]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 24.0
        AML_defining_recurrent_genetic_abnormalities:
          bZIP: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with CEBPA mutation (WHO 2022)
        actual: AML with CEBPA mutation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 24.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: bZIP'
        - bZIP with blasts >=20 => AML with CEBPA mutation
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with CEBPA mutation (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_defining_genetic_abnormalities_who2022[13]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_who2022
      input_data:
        blasts_percentage: 27.0
        AML_defining_recurrent_genetic_abnormalities:
          BCR::ABL1: true
          NPM1: false
        qualifiers: {}
      who_2022:
        expected: AML with BCR::ABL1 fusion (WHO 2022)
        actual: AML with BCR::ABL1 fusion (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 27.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: BCR::ABL1'
        - BCR::ABL1 with blasts >=20 => AML with BCR::ABL1 fusion
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with BCR::ABL1 fusion (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_special_cases_who2022[0]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_special_cases_who2022
      input_data:
        blasts_percentage: 15.0
        AML_defining_recurrent_genetic_abnormalities:
          CEBPA: true
          NPM1: false
      who_2022:
        expected: Not AML, consider MDS classification
        actual: Not AML, consider MDS classification
        derivation:
        - 'Retrieved blasts_percentage: 15.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: CEBPA'
        - CEBPA found but blasts <20 => not AML by this route
        - No AML-defining abnormality fully matched, blasts <20 => consider MDS.
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => Not AML, consider MDS classification
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_special_cases_who2022[1]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_special_cases_who2022
      input_data:
        blasts_percentage: 18.0
        AML_defining_recurrent_genetic_abnormalities:
          bZIP: true
          NPM1: false
      who_2022:
        expected: Not AML, consider MDS classification
        actual: Not AML, consider MDS classification
        derivation:
        - 'Retrieved blasts_percentage: 18.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: bZIP'
        - bZIP found but blasts <20 => not AML by this route
        - No AML-defining abnormality fully matched, blasts <20 => consider MDS.
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => Not AML, consider MDS classification
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_special_cases_who2022[2]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_special_cases_who2022
      input_data:
        blasts_percentage: 12.0
        AML_defining_recurrent_genetic_abnormalities:
          BCR::ABL1: true
          NPM1: false
      who_2022:
        expected: Not AML, consider MDS classification
        actual: Not AML, consider MDS classification
        derivation:
        - 'Retrieved blasts_percentage: 12.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: BCR::ABL1'
        - BCR::ABL1 found but blasts <20 => not AML by this route
        - No AML-defining abnormality fully matched, blasts <20 => consider MDS.
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => Not AML, consider MDS classification
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_special_cases_who2022[3]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_special_cases_who2022
      input_data:
        blasts_percentage: 25.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation:
          ASXL1: true
          SF3B1: false
        MDS_related_cytogenetics: {}
      who_2022:
        expected: AML, myelodysplasia related (WHO 2022)
        actual: AML, myelodysplasia related (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - 'MDS-related mutation(s): ASXL1 => AML, myelodysplasia related'
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML, myelodysplasia related (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022BasicClassification::test_aml_special_cases_who2022[4]
      test_class: TestAMLWHO2022BasicClassification
      test_method: test_aml_special_cases_who2022
      input_data:
        blasts_percentage: 30.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics:
          Complex_karyotype: true
          del_5q: false
      who_2022:
        expected: AML, myelodysplasia related (WHO 2022)
        actual: AML, myelodysplasia related (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - 'MDS-related cytogenetic(s): Complex_karyotype => AML, myelodysplasia related'
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML, myelodysplasia related (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[0]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 25.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M0
      who_2022:
        expected: Acute myeloid leukaemia with minimal differentiation (WHO 2022)
        actual: Acute myeloid leukaemia with minimal differentiation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M0'
        - FAB mapping => Acute myeloid leukaemia with minimal differentiation
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute myeloid leukaemia with minimal differentiation
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[1]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 30.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M1
      who_2022:
        expected: Acute myeloid leukaemia without maturation (WHO 2022)
        actual: Acute myeloid leukaemia without maturation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M1'
        - FAB mapping => Acute myeloid leukaemia without maturation
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute myeloid leukaemia without maturation (WHO
          2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[2]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 35.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M2
      who_2022:
        expected: Acute myeloid leukaemia with maturation (WHO 2022)
        actual: Acute myeloid leukaemia with maturation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 35.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M2'
        - FAB mapping => Acute myeloid leukaemia with maturation
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute myeloid leukaemia with maturation (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[3]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 40.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M3
      who_2022:
        expected: Acute promyelocytic leukaemia (WHO 2022)
        actual: Acute promyelocytic leukaemia (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 40.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M3'
        - FAB mapping => Acute promyelocytic leukaemia
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute promyelocytic leukaemia (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[4]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 45.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M4
      who_2022:
        expected: Acute myelomonocytic leukaemia (WHO 2022)
        actual: Acute myelomonocytic leukaemia (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 45.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M4'
        - FAB mapping => Acute myelomonocytic leukaemia
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute myelomonocytic leukaemia (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[5]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 28.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M4Eo
      who_2022:
        expected: Acute myelomonocytic leukaemia with eosinophilia (WHO 2022)
        actual: Acute myelomonocytic leukaemia with eosinophilia (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 28.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M4Eo'
        - FAB mapping => Acute myelomonocytic leukaemia with eosinophilia
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute myelomonocytic leukaemia with eosinophilia
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[6]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 32.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M5a
      who_2022:
        expected: Acute monoblastic leukaemia (WHO 2022)
        actual: Acute monoblastic leukaemia (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 32.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M5a'
        - FAB mapping => Acute monoblastic leukaemia
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute monoblastic leukaemia (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[7]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 37.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M5b
      who_2022:
        expected: Acute monocytic leukaemia (WHO 2022)
        actual: Acute monocytic leukaemia (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 37.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M5b'
        - FAB mapping => Acute monocytic leukaemia
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute monocytic leukaemia (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[8]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 42.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M6a
      who_2022:
        expected: Acute Erythroid leukaemia (WHO 2022)
        actual: Acute Erythroid leukaemia (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 42.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M6a'
        - Erythroid subtype => Acute Erythroid leukaemia
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute Erythroid leukaemia (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[9]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 26.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M6b
      who_2022:
        expected: Acute Erythroid leukaemia (WHO 2022)
        actual: Acute Erythroid leukaemia (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 26.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M6b'
        - Erythroid subtype => Acute Erythroid leukaemia
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute Erythroid leukaemia (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[10]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 48.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M7
      who_2022:
        expected: Acute megakaryoblastic leukaemia (WHO 2022)
        actual: Acute megakaryoblastic leukaemia (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 48.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M7'
        - FAB mapping => Acute megakaryoblastic leukaemia
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute megakaryoblastic leukaemia (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022FABDifferentiation::test_fab_differentiation_who2022[11]
      test_class: TestAMLWHO2022FABDifferentiation
      test_method: test_fab_differentiation_who2022
      input_data:
        blasts_percentage: 29.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M6a
      who_2022:
        expected: Acute myeloid leukaemia, [define by differentiation] (WHO 2022)
        actual: Acute myeloid leukaemia, [define by differentiation] (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 29.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M6a'
        - not_erythroid flag => skipping erythroid override
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute myeloid leukaemia, [define by differentiation]
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[0]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 25.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
        qualifiers:
          previous_cytotoxic_therapy: Ionising radiation
      who_2022:
        expected: AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)
        actual: AML with NPM1 mutation, previous cytotoxic therapy (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: NPM1'
        - NPM1 => AML with NPM1 mutation
        - No AML_differentiation provided.
        - 'Detected WHO therapy => previous cytotoxic therapy: Ionising radiation'
        - No germline predisposition indicated (review at MDT)
        - Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic
          therapy
        - Final classification => AML with NPM1 mutation, previous cytotoxic therapy
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[1]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 30.0
        AML_defining_recurrent_genetic_abnormalities:
          RUNX1::RUNX1T1: true
        qualifiers:
          previous_cytotoxic_therapy: Cytotoxic chemotherapy
      who_2022:
        expected: AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO
          2022)
        actual: AML with RUNX1::RUNX1T1 fusion, previous cytotoxic therapy (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: RUNX1::RUNX1T1'
        - RUNX1::RUNX1T1 => AML with RUNX1::RUNX1T1 fusion
        - No AML_differentiation provided.
        - 'Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy'
        - No germline predisposition indicated (review at MDT)
        - Classification with qualifiers => AML with RUNX1::RUNX1T1 fusion, previous
          cytotoxic therapy
        - Final classification => AML with RUNX1::RUNX1T1 fusion, previous cytotoxic
          therapy (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[2]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 35.0
        AML_defining_recurrent_genetic_abnormalities:
          CBFB::MYH11: true
        qualifiers:
          previous_cytotoxic_therapy: Any combination
      who_2022:
        expected: AML with CBFB::MYH11 fusion, previous cytotoxic therapy (WHO 2022)
        actual: AML with CBFB::MYH11 fusion, previous cytotoxic therapy (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 35.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: CBFB::MYH11'
        - CBFB::MYH11 => AML with CBFB::MYH11 fusion
        - No AML_differentiation provided.
        - 'Detected WHO therapy => previous cytotoxic therapy: Any combination'
        - No germline predisposition indicated (review at MDT)
        - Classification with qualifiers => AML with CBFB::MYH11 fusion, previous
          cytotoxic therapy
        - Final classification => AML with CBFB::MYH11 fusion, previous cytotoxic
          therapy (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[3]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 28.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
        qualifiers:
          previous_cytotoxic_therapy: Immune interventions
      who_2022:
        expected: AML with NPM1 mutation (WHO 2022)
        actual: AML with NPM1 mutation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 28.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: NPM1'
        - NPM1 => AML with NPM1 mutation
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with NPM1 mutation (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[4]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 40.0
        AML_defining_recurrent_genetic_abnormalities:
          DEK::NUP214: true
        qualifiers:
          predisposing_germline_variant: RUNX1
      who_2022:
        expected: AML with DEK::NUP214 fusion, associated with RUNX1 (WHO 2022)
        actual: AML with DEK::NUP214 fusion, associated with RUNX1 (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 40.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: DEK::NUP214'
        - DEK::NUP214 => AML with DEK::NUP214 fusion
        - No AML_differentiation provided.
        - Detected germline predisposition => associated with RUNX1
        - Classification with qualifiers => AML with DEK::NUP214 fusion, associated
          with RUNX1
        - Final classification => AML with DEK::NUP214 fusion, associated with RUNX1
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[5]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 33.0
        AML_defining_recurrent_genetic_abnormalities:
          RBM15::MRTFA: true
        qualifiers:
          predisposing_germline_variant: GATA2, DDX41
      who_2022:
        expected: AML with RBM15::MRTFA fusion, associated with GATA2, DDX41 (WHO
          2022)
        actual: AML with RBM15::MRTFA fusion, associated with GATA2, DDX41 (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 33.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: RBM15::MRTFA'
        - RBM15::MRTFA => AML with RBM15::MRTFA fusion
        - No AML_differentiation provided.
        - Detected germline predisposition => associated with GATA2, DDX41
        - Classification with qualifiers => AML with RBM15::MRTFA fusion, associated
          with GATA2, DDX41
        - Final classification => AML with RBM15::MRTFA fusion, associated with GATA2,
          DDX41 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[6]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 26.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
        qualifiers:
          predisposing_germline_variant: Diamond-Blackfan anemia
      who_2022:
        expected: AML with NPM1 mutation (WHO 2022)
        actual: AML with NPM1 mutation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 26.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: NPM1'
        - NPM1 => AML with NPM1 mutation
        - No AML_differentiation provided.
        - Final classification => AML with NPM1 mutation (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[7]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 31.0
        AML_defining_recurrent_genetic_abnormalities:
          KMT2A: true
        qualifiers:
          previous_MDS_diagnosed_over_3_months_ago: true
      who_2022:
        expected: AML with KMT2A rearrangement, progressed from MDS (WHO 2022)
        actual: AML with KMT2A rearrangement, progressed from MDS (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 31.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: KMT2A'
        - KMT2A => AML with KMT2A rearrangement
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Either previous_MDS, previous_MDS/MPN, or previous_MPN is True => 'progressed
          from MDS'
        - Classification with qualifiers => AML with KMT2A rearrangement, progressed
          from MDS
        - Final classification => AML with KMT2A rearrangement, progressed from MDS
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[8]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 38.0
        AML_defining_recurrent_genetic_abnormalities:
          MECOM: true
        qualifiers:
          previous_MDS/MPN_diagnosed_over_3_months_ago: true
      who_2022:
        expected: AML with MECOM rearrangement, progressed from MDS (WHO 2022)
        actual: AML with MECOM rearrangement, progressed from MDS (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 38.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: MECOM'
        - MECOM => AML with MECOM rearrangement
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Either previous_MDS, previous_MDS/MPN, or previous_MPN is True => 'progressed
          from MDS'
        - Classification with qualifiers => AML with MECOM rearrangement, progressed
          from MDS
        - Final classification => AML with MECOM rearrangement, progressed from MDS
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[9]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 44.0
        AML_defining_recurrent_genetic_abnormalities:
          NUP98: true
        qualifiers:
          previous_MPN_diagnosed_over_3_months_ago: true
      who_2022:
        expected: AML with NUP98 rearrangement, progressed from MDS (WHO 2022)
        actual: AML with NUP98 rearrangement, progressed from MDS (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 44.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: NUP98'
        - NUP98 => AML with NUP98 rearrangement
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Either previous_MDS, previous_MDS/MPN, or previous_MPN is True => 'progressed
          from MDS'
        - Classification with qualifiers => AML with NUP98 rearrangement, progressed
          from MDS
        - Final classification => AML with NUP98 rearrangement, progressed from MDS
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLWHO2022Qualifiers::test_aml_who2022_qualifiers[10]
      test_class: TestAMLWHO2022Qualifiers
      test_method: test_aml_who2022_qualifiers
      input_data:
        blasts_percentage: 27.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
        qualifiers:
          previous_cytotoxic_therapy: Cytotoxic chemotherapy
          predisposing_germline_variant: GATA2
          previous_MDS_diagnosed_over_3_months_ago: true
      who_2022:
        expected: AML with NPM1 mutation, previous cytotoxic therapy, associated with
          GATA2, progressed from MDS (WHO 2022)
        actual: AML with NPM1 mutation, previous cytotoxic therapy, associated with
          GATA2, progressed from MDS (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 27.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: NPM1'
        - NPM1 => AML with NPM1 mutation
        - No AML_differentiation provided.
        - 'Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy'
        - Detected germline predisposition => associated with GATA2
        - Either previous_MDS, previous_MDS/MPN, or previous_MPN is True => 'progressed
          from MDS'
        - Classification with qualifiers => AML with NPM1 mutation, previous cytotoxic
          therapy, associated with GATA2, progressed from MDS
        - Final classification => AML with NPM1 mutation, previous cytotoxic therapy,
          associated with GATA2, progressed from MDS (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[0]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 25.0
        AML_defining_recurrent_genetic_abnormalities:
          PML::RARA: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: APL with t(15;17)(q24.1;q21.2)/PML::RARA (ICC 2022)
        actual: APL with t(15;17)(q24.1;q21.2)/PML::RARA (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => PML::RARA
        - PML::RARA => APL with t(15;17)(q24.1;q21.2)/PML::RARA
        - No germline predisposition indicated (review at MDT)
        - Final => APL with t(15;17)(q24.1;q21.2)/PML::RARA (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[1]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 30.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
          PML::RARA: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with mutated NPM1 (ICC 2022)
        actual: AML with mutated NPM1 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => NPM1
        - NPM1 => AML with mutated NPM1
        - No germline predisposition indicated (review at MDT)
        - Final => AML with mutated NPM1 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[2]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 15.0
        AML_defining_recurrent_genetic_abnormalities:
          RUNX1::RUNX1T1: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)
        actual: AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 15.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => RUNX1::RUNX1T1
        - RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1
        - No germline predisposition indicated (review at MDT)
        - Final => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[3]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 12.0
        AML_defining_recurrent_genetic_abnormalities:
          CBFB::MYH11: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 (ICC
          2022)
        actual: AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 (ICC
          2022)
        derivation:
        - 'Retrieved blasts_percentage: 12.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => CBFB::MYH11
        - CBFB::MYH11 => AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11
        - No germline predisposition indicated (review at MDT)
        - Final => AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11 (ICC
          2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[4]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 18.0
        AML_defining_recurrent_genetic_abnormalities:
          DEK::NUP214: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with t(6;9)(p22.3;q34.1)/DEK::NUP214 (ICC 2022)
        actual: AML with t(6;9)(p22.3;q34.1)/DEK::NUP214 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 18.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => DEK::NUP214
        - DEK::NUP214 => AML with t(6;9)(p22.3;q34.1)/DEK::NUP214
        - No germline predisposition indicated (review at MDT)
        - Final => AML with t(6;9)(p22.3;q34.1)/DEK::NUP214 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[5]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 22.0
        AML_defining_recurrent_genetic_abnormalities:
          RBM15::MRTFA: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML (megakaryoblastic) with t(1;22)(p13.3;q13.1)/RBM15::MRTFA (ICC
          2022)
        actual: AML (megakaryoblastic) with t(1;22)(p13.3;q13.1)/RBM15::MRTFA (ICC
          2022)
        derivation:
        - 'Retrieved blasts_percentage: 22.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => RBM15::MRTFA
        - RBM15::MRTFA => AML (megakaryoblastic) with t(1;22)(p13.3;q13.1)/RBM15::MRTFA
        - No germline predisposition indicated (review at MDT)
        - Final => AML (megakaryoblastic) with t(1;22)(p13.3;q13.1)/RBM15::MRTFA (ICC
          2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[6]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 16.0
        AML_defining_recurrent_genetic_abnormalities:
          MLLT3::KMT2A: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A (ICC 2022)
        actual: AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 16.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => MLLT3::KMT2A
        - MLLT3::KMT2A => AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A
        - No germline predisposition indicated (review at MDT)
        - Final => AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[7]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 24.0
        AML_defining_recurrent_genetic_abnormalities:
          GATA2::MECOM: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EVI1)
          (ICC 2022)
        actual: AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EVI1)
          (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 24.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => GATA2::MECOM
        - GATA2::MECOM => AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2,
          MECOM(EVI1)
        - No germline predisposition indicated (review at MDT)
        - Final => AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2)/GATA2, MECOM(EVI1)
          (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[8]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 28.0
        AML_defining_recurrent_genetic_abnormalities:
          KMT2A: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with other KMT2A rearrangements (ICC 2022)
        actual: AML with other KMT2A rearrangements (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 28.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => KMT2A
        - KMT2A => AML with other KMT2A rearrangements
        - No germline predisposition indicated (review at MDT)
        - Final => AML with other KMT2A rearrangements (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[9]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 32.0
        AML_defining_recurrent_genetic_abnormalities:
          MECOM: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with other MECOM rearrangements (ICC 2022)
        actual: AML with other MECOM rearrangements (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 32.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => MECOM
        - MECOM => AML with other MECOM rearrangements
        - No germline predisposition indicated (review at MDT)
        - Final => AML with other MECOM rearrangements (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[10]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 26.0
        AML_defining_recurrent_genetic_abnormalities:
          NUP98: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with NUP98 and other partners (ICC 2022)
        actual: AML with NUP98 and other partners (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 26.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => NUP98
        - NUP98 => AML with NUP98 and other partners
        - No germline predisposition indicated (review at MDT)
        - Final => AML with NUP98 and other partners (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[11]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 14.0
        AML_defining_recurrent_genetic_abnormalities:
          bZIP: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with in-frame bZIP mutated CEBPA (ICC 2022)
        actual: AML with in-frame bZIP mutated CEBPA (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 14.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => bZIP
        - bZIP => AML with in-frame bZIP mutated CEBPA
        - No germline predisposition indicated (review at MDT)
        - Final => AML with in-frame bZIP mutated CEBPA (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_defining_genetic_abnormalities_icc2022[12]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_defining_genetic_abnormalities_icc2022
      input_data:
        blasts_percentage: 19.0
        AML_defining_recurrent_genetic_abnormalities:
          BCR::ABL1: true
          NPM1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
        actual: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 19.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => BCR::ABL1
        - BCR::ABL1 => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1
        - No germline predisposition indicated (review at MDT)
        - Final => AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_special_categories_icc2022[0]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_special_categories_icc2022
      input_data:
        blasts_percentage: 25.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: true
          1_x_TP53_mutation_del_17p: false
          1_x_TP53_mutation_LOH: false
          1_x_TP53_mutation_10_percent_vaf: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with mutated TP53 (ICC 2022)
        actual: AML with mutated TP53 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - Biallelic TP53 => AML with mutated TP53
        - Blasts >=20 => remain AML
        - No germline predisposition indicated (review at MDT)
        - Final => AML with mutated TP53 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_special_categories_icc2022[1]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_special_categories_icc2022
      input_data:
        blasts_percentage: 30.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: false
          1_x_TP53_mutation_del_17p: true
          1_x_TP53_mutation_LOH: false
          1_x_TP53_mutation_10_percent_vaf: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with mutated TP53 (ICC 2022)
        actual: AML with mutated TP53 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - Biallelic TP53 => AML with mutated TP53
        - Blasts >=20 => remain AML
        - No germline predisposition indicated (review at MDT)
        - Final => AML with mutated TP53 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_special_categories_icc2022[2]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_special_categories_icc2022
      input_data:
        blasts_percentage: 35.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: false
          1_x_TP53_mutation_del_17p: false
          1_x_TP53_mutation_LOH: true
          1_x_TP53_mutation_10_percent_vaf: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with mutated TP53 (ICC 2022)
        actual: AML with mutated TP53 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 35.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - Biallelic TP53 => AML with mutated TP53
        - Blasts >=20 => remain AML
        - No germline predisposition indicated (review at MDT)
        - Final => AML with mutated TP53 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_special_categories_icc2022[3]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_special_categories_icc2022
      input_data:
        blasts_percentage: 40.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: false
          1_x_TP53_mutation_del_17p: false
          1_x_TP53_mutation_LOH: false
          1_x_TP53_mutation_10_percent_vaf: true
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with mutated TP53 (ICC 2022)
        actual: AML with mutated TP53 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 40.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - Biallelic TP53 => AML with mutated TP53
        - Blasts >=20 => remain AML
        - No germline predisposition indicated (review at MDT)
        - Final => AML with mutated TP53 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_special_categories_icc2022[4]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_special_categories_icc2022
      input_data:
        blasts_percentage: 28.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation: {}
        MDS_related_mutation:
          ASXL1: true
          SF3B1: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with myelodysplasia related gene mutation (ICC 2022)
        actual: AML with myelodysplasia related gene mutation (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 28.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - No biallelic TP53 conditions met.
        - MDS-related genes => AML with myelodysplasia related gene mutation
        - Blasts >=20 => remain AML
        - No germline predisposition indicated (review at MDT)
        - Final => AML with myelodysplasia related gene mutation (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_special_categories_icc2022[5]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_special_categories_icc2022
      input_data:
        blasts_percentage: 33.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics:
          Complex_karyotype: true
          del_5q: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML with myelodysplasia related cytogenetic abnormality (ICC 2022)
        actual: AML with myelodysplasia related cytogenetic abnormality (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 33.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality
        - Blasts >=20 => remain AML
        - No germline predisposition indicated (review at MDT)
        - Final => AML with myelodysplasia related cytogenetic abnormality (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BasicClassification::test_aml_special_categories_icc2022[6]
      test_class: TestAMLICC2022BasicClassification
      test_method: test_aml_special_categories_icc2022
      input_data:
        blasts_percentage: 25.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: AML, NOS (ICC 2022)
        actual: AML, NOS (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - No MDS-related cytogenetics triggered classification.
        - Blasts >=20 => remain AML
        - No germline predisposition indicated (review at MDT)
        - Final => AML, NOS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BlastThresholds::test_aml_icc2022_blast_thresholds[0]
      test_class: TestAMLICC2022BlastThresholds
      test_method: test_aml_icc2022_blast_thresholds
      input_data:
        blasts_percentage: 8.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
      who_2022: null
      icc_2022:
        expected: Not AML, consider MDS classification
        actual: Not AML, consider MDS classification
        derivation:
        - 'Retrieved blasts_percentage: 8.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => NPM1
        - NPM1 but blasts <10 => cannot label AML here
        - No single ICC AML-def abnormality triggered classification.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - No MDS-related cytogenetics triggered classification.
        - 'Blasts <10 => final classification: Not AML, consider MDS classification'
        - No germline predisposition indicated (review at MDT)
        - Final => Not AML, consider MDS classification
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BlastThresholds::test_aml_icc2022_blast_thresholds[1]
      test_class: TestAMLICC2022BlastThresholds
      test_method: test_aml_icc2022_blast_thresholds
      input_data:
        blasts_percentage: 15.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: true
      who_2022: null
      icc_2022:
        expected: MDS/AML with mutated TP53 (ICC 2022)
        actual: MDS/AML with mutated TP53 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 15.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - Biallelic TP53 => AML with mutated TP53
        - "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification:\
          \ MDS/AML with mutated TP53"
        - No germline predisposition indicated (review at MDT)
        - Final => MDS/AML with mutated TP53 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BlastThresholds::test_aml_icc2022_blast_thresholds[2]
      test_class: TestAMLICC2022BlastThresholds
      test_method: test_aml_icc2022_blast_thresholds
      input_data:
        blasts_percentage: 12.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation: {}
        MDS_related_mutation:
          ASXL1: true
      who_2022: null
      icc_2022:
        expected: MDS/AML with myelodysplasia related gene mutation (ICC 2022)
        actual: MDS/AML with myelodysplasia related gene mutation (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 12.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - No biallelic TP53 conditions met.
        - MDS-related genes => AML with myelodysplasia related gene mutation
        - "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification:\
          \ MDS/AML with myelodysplasia related gene mutation"
        - No germline predisposition indicated (review at MDT)
        - Final => MDS/AML with myelodysplasia related gene mutation (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BlastThresholds::test_aml_icc2022_blast_thresholds[3]
      test_class: TestAMLICC2022BlastThresholds
      test_method: test_aml_icc2022_blast_thresholds
      input_data:
        blasts_percentage: 18.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics:
          del_5q: true
      who_2022: null
      icc_2022:
        expected: MDS/AML with myelodysplasia related cytogenetic abnormality (ICC
          2022)
        actual: MDS/AML with myelodysplasia related cytogenetic abnormality (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 18.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - MDS-related cyto => AML with myelodysplasia related cytogenetic abnormality
        - "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification:\
          \ MDS/AML with myelodysplasia related cytogenetic abnormality"
        - No germline predisposition indicated (review at MDT)
        - Final => MDS/AML with myelodysplasia related cytogenetic abnormality (ICC
          2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BlastThresholds::test_aml_icc2022_blast_thresholds[4]
      test_class: TestAMLICC2022BlastThresholds
      test_method: test_aml_icc2022_blast_thresholds
      input_data:
        blasts_percentage: 14.0
        AML_defining_recurrent_genetic_abnormalities: {}
        Biallelic_TP53_mutation: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
      who_2022: null
      icc_2022:
        expected: MDS/AML, NOS (ICC 2022)
        actual: MDS/AML, NOS (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 14.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - No MDS-related cytogenetics triggered classification.
        - "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification:\
          \ MDS/AML, NOS"
        - No germline predisposition indicated (review at MDT)
        - Final => MDS/AML, NOS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022BlastThresholds::test_aml_icc2022_blast_thresholds[5]
      test_class: TestAMLICC2022BlastThresholds
      test_method: test_aml_icc2022_blast_thresholds
      input_data:
        blasts_percentage: 5.0
        AML_defining_recurrent_genetic_abnormalities:
          RUNX1::RUNX1T1: true
      who_2022: null
      icc_2022:
        expected: Not AML, consider MDS classification
        actual: Not AML, consider MDS classification
        derivation:
        - 'Retrieved blasts_percentage: 5.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => RUNX1::RUNX1T1
        - RUNX1::RUNX1T1 but blasts <10 => cannot label AML here
        - No single ICC AML-def abnormality triggered classification.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - No MDS-related cytogenetics triggered classification.
        - 'Blasts <10 => final classification: Not AML, consider MDS classification'
        - No germline predisposition indicated (review at MDT)
        - Final => Not AML, consider MDS classification
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[0]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 25.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
        qualifiers:
          previous_cytotoxic_therapy: Ionising radiation
      who_2022: null
      icc_2022:
        expected: AML with mutated NPM1, therapy related (ICC 2022)
        actual: AML with mutated NPM1, therapy related (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => NPM1
        - NPM1 => AML with mutated NPM1
        - 'Detected ICC therapy => therapy related: Ionising radiation'
        - No germline predisposition indicated (review at MDT)
        - Qualifiers appended => AML with mutated NPM1, therapy related (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[1]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 30.0
        AML_defining_recurrent_genetic_abnormalities:
          RUNX1::RUNX1T1: true
        qualifiers:
          previous_cytotoxic_therapy: Cytotoxic chemotherapy
      who_2022: null
      icc_2022:
        expected: AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC
          2022)
        actual: AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy related (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => RUNX1::RUNX1T1
        - RUNX1::RUNX1T1 => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1
        - 'Detected ICC therapy => therapy related: Cytotoxic chemotherapy'
        - No germline predisposition indicated (review at MDT)
        - Qualifiers appended => AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1, therapy
          related (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[2]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 35.0
        AML_defining_recurrent_genetic_abnormalities:
          CBFB::MYH11: true
        qualifiers:
          previous_cytotoxic_therapy: Immune interventions
      who_2022: null
      icc_2022:
        expected: AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11, therapy
          related (ICC 2022)
        actual: AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11, therapy
          related (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 35.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => CBFB::MYH11
        - CBFB::MYH11 => AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11
        - 'Detected ICC therapy => therapy related: Immune interventions'
        - No germline predisposition indicated (review at MDT)
        - Qualifiers appended => AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11,
          therapy related (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[3]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 28.0
        AML_defining_recurrent_genetic_abnormalities:
          DEK::NUP214: true
        qualifiers:
          previous_cytotoxic_therapy: Any combination
      who_2022: null
      icc_2022:
        expected: AML with t(6;9)(p22.3;q34.1)/DEK::NUP214, therapy related (ICC 2022)
        actual: AML with t(6;9)(p22.3;q34.1)/DEK::NUP214, therapy related (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 28.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => DEK::NUP214
        - DEK::NUP214 => AML with t(6;9)(p22.3;q34.1)/DEK::NUP214
        - 'Detected ICC therapy => therapy related: Any combination'
        - No germline predisposition indicated (review at MDT)
        - Qualifiers appended => AML with t(6;9)(p22.3;q34.1)/DEK::NUP214, therapy
          related (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[4]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 40.0
        AML_defining_recurrent_genetic_abnormalities:
          RBM15::MRTFA: true
        qualifiers:
          predisposing_germline_variant: RUNX1
      who_2022: null
      icc_2022:
        expected: AML (megakaryoblastic) with t(1;22)(p13.3;q13.1)/RBM15::MRTFA, in
          the setting of RUNX1 (ICC 2022)
        actual: AML (megakaryoblastic) with t(1;22)(p13.3;q13.1)/RBM15::MRTFA, in
          the setting of RUNX1 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 40.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => RBM15::MRTFA
        - RBM15::MRTFA => AML (megakaryoblastic) with t(1;22)(p13.3;q13.1)/RBM15::MRTFA
        - Qualifier => in the setting of RUNX1
        - Qualifiers appended => AML (megakaryoblastic) with t(1;22)(p13.3;q13.1)/RBM15::MRTFA,
          in the setting of RUNX1 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[5]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 33.0
        AML_defining_recurrent_genetic_abnormalities:
          MLLT3::KMT2A: true
        qualifiers:
          predisposing_germline_variant: GATA2, DDX41
      who_2022: null
      icc_2022:
        expected: AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A, in the setting of GATA2,
          DDX41 (ICC 2022)
        actual: AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A, in the setting of GATA2,
          DDX41 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 33.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => MLLT3::KMT2A
        - MLLT3::KMT2A => AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A
        - Qualifier => in the setting of GATA2, DDX41
        - Qualifiers appended => AML with t(9;11)(p21.3;q23.3)/MLLT3::KMT2A, in the
          setting of GATA2, DDX41 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[6]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 26.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
        qualifiers:
          predisposing_germline_variant: germline BLM mutation
      who_2022: null
      icc_2022:
        expected: AML with mutated NPM1 (ICC 2022)
        actual: AML with mutated NPM1 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 26.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => NPM1
        - NPM1 => AML with mutated NPM1
        - Final => AML with mutated NPM1 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[7]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 31.0
        AML_defining_recurrent_genetic_abnormalities:
          KMT2A: true
        qualifiers:
          previous_MDS_diagnosed_over_3_months_ago: true
      who_2022: null
      icc_2022:
        expected: AML with other KMT2A rearrangements, arising post MDS (ICC 2022)
        actual: AML with other KMT2A rearrangements, arising post MDS (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 31.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => KMT2A
        - KMT2A => AML with other KMT2A rearrangements
        - No germline predisposition indicated (review at MDT)
        - Either previous_MDS, previous_MDS/MPN, or previous_MPN => 'arising post
          MDS'
        - Qualifiers appended => AML with other KMT2A rearrangements, arising post
          MDS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[8]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 38.0
        AML_defining_recurrent_genetic_abnormalities:
          MECOM: true
        qualifiers:
          previous_MDS/MPN_diagnosed_over_3_months_ago: true
      who_2022: null
      icc_2022:
        expected: AML with other MECOM rearrangements, arising post MDS (ICC 2022)
        actual: AML with other MECOM rearrangements, arising post MDS (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 38.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => MECOM
        - MECOM => AML with other MECOM rearrangements
        - No germline predisposition indicated (review at MDT)
        - Either previous_MDS, previous_MDS/MPN, or previous_MPN => 'arising post
          MDS'
        - Qualifiers appended => AML with other MECOM rearrangements, arising post
          MDS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[9]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 44.0
        AML_defining_recurrent_genetic_abnormalities:
          NUP98: true
        qualifiers:
          previous_MPN_diagnosed_over_3_months_ago: true
      who_2022: null
      icc_2022:
        expected: AML with NUP98 and other partners, arising post MDS (ICC 2022)
        actual: AML with NUP98 and other partners, arising post MDS (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 44.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => NUP98
        - NUP98 => AML with NUP98 and other partners
        - No germline predisposition indicated (review at MDT)
        - Either previous_MDS, previous_MDS/MPN, or previous_MPN => 'arising post
          MDS'
        - Qualifiers appended => AML with NUP98 and other partners, arising post MDS
          (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLICC2022Qualifiers::test_aml_icc2022_qualifiers[10]
      test_class: TestAMLICC2022Qualifiers
      test_method: test_aml_icc2022_qualifiers
      input_data:
        blasts_percentage: 27.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
        qualifiers:
          previous_cytotoxic_therapy: Cytotoxic chemotherapy
          predisposing_germline_variant: GATA2
          previous_MDS_diagnosed_over_3_months_ago: true
      who_2022: null
      icc_2022:
        expected: AML with mutated NPM1, therapy related, in the setting of GATA2,
          arising post MDS (ICC 2022)
        actual: AML with mutated NPM1, therapy related, in the setting of GATA2, arising
          post MDS (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 27.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => NPM1
        - NPM1 => AML with mutated NPM1
        - 'Detected ICC therapy => therapy related: Cytotoxic chemotherapy'
        - Qualifier => in the setting of GATA2
        - Either previous_MDS, previous_MDS/MPN, or previous_MPN => 'arising post
          MDS'
        - Qualifiers appended => AML with mutated NPM1, therapy related, in the setting
          of GATA2, arising post MDS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLEdgeCases::test_aml_edge_cases[0]
      test_class: TestAMLEdgeCases
      test_method: test_aml_edge_cases
      input_data:
        blasts_percentage: 20.0
        AML_defining_recurrent_genetic_abnormalities:
          CEBPA: true
      who_2022:
        expected: AML with CEBPA mutation (WHO 2022)
        actual: AML with CEBPA mutation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 20.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: CEBPA'
        - CEBPA with blasts >=20 => AML with CEBPA mutation
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with CEBPA mutation (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: AML, NOS (ICC 2022)
        actual: AML, NOS (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 20.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => CEBPA
        - No single ICC AML-def abnormality triggered classification.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - No MDS-related cytogenetics triggered classification.
        - Blasts >=20 => remain AML
        - No germline predisposition indicated (review at MDT)
        - Final => AML, NOS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLEdgeCases::test_aml_edge_cases[1]
      test_class: TestAMLEdgeCases
      test_method: test_aml_edge_cases
      input_data:
        blasts_percentage: 19.9
        AML_defining_recurrent_genetic_abnormalities:
          CEBPA: true
      who_2022:
        expected: Not AML, consider MDS classification
        actual: Not AML, consider MDS classification
        derivation:
        - 'Retrieved blasts_percentage: 19.9'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: CEBPA'
        - CEBPA found but blasts <20 => not AML by this route
        - No AML-defining abnormality fully matched, blasts <20 => consider MDS.
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => Not AML, consider MDS classification
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: MDS/AML, NOS (ICC 2022)
        actual: MDS/AML, NOS (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 19.9'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => CEBPA
        - No single ICC AML-def abnormality triggered classification.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - No MDS-related cytogenetics triggered classification.
        - "Blasts 10\u201319 => replaced 'AML' with 'MDS/AML'. Final classification:\
          \ MDS/AML, NOS"
        - No germline predisposition indicated (review at MDT)
        - Final => MDS/AML, NOS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLEdgeCases::test_aml_edge_cases[2]
      test_class: TestAMLEdgeCases
      test_method: test_aml_edge_cases
      input_data:
        blasts_percentage: 10.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
      who_2022:
        expected: AML with NPM1 mutation (WHO 2022)
        actual: AML with NPM1 mutation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 10.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: NPM1'
        - NPM1 => AML with NPM1 mutation
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with NPM1 mutation (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: AML with mutated NPM1 (ICC 2022)
        actual: AML with mutated NPM1 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 10.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => NPM1
        - NPM1 => AML with mutated NPM1
        - No germline predisposition indicated (review at MDT)
        - Final => AML with mutated NPM1 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLEdgeCases::test_aml_edge_cases[3]
      test_class: TestAMLEdgeCases
      test_method: test_aml_edge_cases
      input_data:
        blasts_percentage: 9.9
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
      who_2022:
        expected: AML with NPM1 mutation (WHO 2022)
        actual: AML with NPM1 mutation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 9.9'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: NPM1'
        - NPM1 => AML with NPM1 mutation
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with NPM1 mutation (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: Not AML, consider MDS classification
        actual: Not AML, consider MDS classification
        derivation:
        - 'Retrieved blasts_percentage: 9.9'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => NPM1
        - NPM1 but blasts <10 => cannot label AML here
        - No single ICC AML-def abnormality triggered classification.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - No MDS-related cytogenetics triggered classification.
        - 'Blasts <10 => final classification: Not AML, consider MDS classification'
        - No germline predisposition indicated (review at MDT)
        - Final => Not AML, consider MDS classification
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLEdgeCases::test_aml_edge_cases[4]
      test_class: TestAMLEdgeCases
      test_method: test_aml_edge_cases
      input_data:
        blasts_percentage: 25.0
        AML_defining_recurrent_genetic_abnormalities:
          PML::RARA: true
          NPM1: true
          RUNX1::RUNX1T1: true
      who_2022:
        expected: Acute promyelocytic leukaemia with PML::RARA fusion (WHO 2022)
        actual: Acute promyelocytic leukaemia with PML::RARA fusion (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: PML::RARA, NPM1, RUNX1::RUNX1T1'
        - PML::RARA => Acute promyelocytic leukaemia with PML::RARA fusion
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute promyelocytic leukaemia with PML::RARA fusion
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: APL with t(15;17)(q24.1;q21.2)/PML::RARA (ICC 2022)
        actual: APL with t(15;17)(q24.1;q21.2)/PML::RARA (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => PML::RARA, NPM1, RUNX1::RUNX1T1
        - PML::RARA => APL with t(15;17)(q24.1;q21.2)/PML::RARA
        - No germline predisposition indicated (review at MDT)
        - Final => APL with t(15;17)(q24.1;q21.2)/PML::RARA (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLEdgeCases::test_aml_edge_cases[5]
      test_class: TestAMLEdgeCases
      test_method: test_aml_edge_cases
      input_data:
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
      who_2022:
        expected: 'Error: blasts_percentage is missing. Classification cannot proceed.'
        actual: 'Error: blasts_percentage is missing. Classification cannot proceed.'
        derivation:
        - 'Retrieved blasts_percentage: None'
        - 'Error: blasts_percentage is missing. Classification cannot proceed.'
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: 'Error: blasts_percentage is missing. Classification cannot proceed.'
        actual: 'Error: blasts_percentage is missing. Classification cannot proceed.'
        derivation:
        - 'Retrieved blasts_percentage: None'
        - 'Error: blasts_percentage is missing. Classification cannot proceed.'
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLEdgeCases::test_aml_edge_cases[6]
      test_class: TestAMLEdgeCases
      test_method: test_aml_edge_cases
      input_data:
        blasts_percentage: -5.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
      who_2022:
        expected: 'Error: blasts_percentage must be a number between 0 and 100.'
        actual: 'Error: blasts_percentage must be a number between 0 and 100.'
        derivation:
        - 'Retrieved blasts_percentage: -5.0'
        - 'Error: blasts_percentage must be a number between 0 and 100.'
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: 'Error: blasts_percentage must be a number between 0 and 100.'
        actual: 'Error: blasts_percentage must be a number between 0 and 100.'
        derivation:
        - 'Retrieved blasts_percentage: -5.0'
        - 'Error: blasts_percentage must be a number between 0 and 100.'
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLEdgeCases::test_aml_edge_cases[7]
      test_class: TestAMLEdgeCases
      test_method: test_aml_edge_cases
      input_data:
        blasts_percentage: 105.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
      who_2022:
        expected: 'Error: blasts_percentage must be a number between 0 and 100.'
        actual: 'Error: blasts_percentage must be a number between 0 and 100.'
        derivation:
        - 'Retrieved blasts_percentage: 105.0'
        - 'Error: blasts_percentage must be a number between 0 and 100.'
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: 'Error: blasts_percentage must be a number between 0 and 100.'
        actual: 'Error: blasts_percentage must be a number between 0 and 100.'
        derivation:
        - 'Retrieved blasts_percentage: 105.0'
        - 'Error: blasts_percentage must be a number between 0 and 100.'
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLComplexScenarios::test_complex_aml_scenarios[0]
      test_class: TestAMLComplexScenarios
      test_method: test_complex_aml_scenarios
      input_data:
        blasts_percentage: 28.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation:
          ASXL1: true
          SF3B1: true
          SRSF2: false
        MDS_related_cytogenetics:
          Complex_karyotype: true
          del_5q: true
        qualifiers:
          previous_cytotoxic_therapy: Cytotoxic chemotherapy
          predisposing_germline_variant: GATA2
          previous_MDS_diagnosed_over_3_months_ago: true
      who_2022:
        expected: AML, myelodysplasia related, previous cytotoxic therapy, associated
          with GATA2, progressed from MDS (WHO 2022)
        actual: AML, myelodysplasia related, previous cytotoxic therapy, associated
          with GATA2, progressed from MDS (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 28.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - 'MDS-related mutation(s): ASXL1, SF3B1 => AML, myelodysplasia related'
        - No AML_differentiation provided.
        - 'Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy'
        - Detected germline predisposition => associated with GATA2
        - Either previous_MDS, previous_MDS/MPN, or previous_MPN is True => 'progressed
          from MDS'
        - Classification with qualifiers => AML, myelodysplasia related, previous
          cytotoxic therapy, associated with GATA2, progressed from MDS
        - Final classification => AML, myelodysplasia related, previous cytotoxic
          therapy, associated with GATA2, progressed from MDS (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: AML with myelodysplasia related gene mutation, therapy related,
          in the setting of GATA2, arising post MDS (ICC 2022)
        actual: AML with myelodysplasia related gene mutation, therapy related, in
          the setting of GATA2, arising post MDS (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 28.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - No biallelic TP53 conditions met.
        - MDS-related genes => AML with myelodysplasia related gene mutation
        - Blasts >=20 => remain AML
        - 'Detected ICC therapy => therapy related: Cytotoxic chemotherapy'
        - Qualifier => in the setting of GATA2
        - Either previous_MDS, previous_MDS/MPN, or previous_MPN => 'arising post
          MDS'
        - Qualifiers appended => AML with myelodysplasia related gene mutation, therapy
          related, in the setting of GATA2, arising post MDS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLComplexScenarios::test_complex_aml_scenarios[1]
      test_class: TestAMLComplexScenarios
      test_method: test_complex_aml_scenarios
      input_data:
        blasts_percentage: 35.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M4
        qualifiers:
          previous_cytotoxic_therapy: Ionising radiation
          predisposing_germline_variant: RUNX1
      who_2022:
        expected: Acute myelomonocytic leukaemia, previous cytotoxic therapy, associated
          with RUNX1 (WHO 2022)
        actual: Acute myelomonocytic leukaemia, previous cytotoxic therapy, associated
          with RUNX1 (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 35.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M4'
        - FAB mapping => Acute myelomonocytic leukaemia
        - 'Detected WHO therapy => previous cytotoxic therapy: Ionising radiation'
        - Detected germline predisposition => associated with RUNX1
        - Classification with qualifiers => Acute myelomonocytic leukaemia, previous
          cytotoxic therapy, associated with RUNX1
        - Final classification => Acute myelomonocytic leukaemia, previous cytotoxic
          therapy, associated with RUNX1 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: AML, NOS, therapy related, in the setting of RUNX1 (ICC 2022)
        actual: AML, NOS, therapy related, in the setting of RUNX1 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 35.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - No MDS-related cytogenetics triggered classification.
        - Blasts >=20 => remain AML
        - 'Detected ICC therapy => therapy related: Ionising radiation'
        - Qualifier => in the setting of RUNX1
        - Qualifiers appended => AML, NOS, therapy related, in the setting of RUNX1
          (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLComplexScenarios::test_complex_aml_scenarios[2]
      test_class: TestAMLComplexScenarios
      test_method: test_complex_aml_scenarios
      input_data:
        blasts_percentage: 30.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        AML_differentiation: M6a
        qualifiers: {}
      who_2022:
        expected: Acute myeloid leukaemia, [define by differentiation] (WHO 2022)
        actual: Acute myeloid leukaemia, [define by differentiation] (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - No MDS-related mutations found.
        - No MDS-related cytogenetic flags found.
        - 'AML_differentiation: M6a'
        - not_erythroid flag => skipping erythroid override
        - No germline predisposition indicated (review at MDT)
        - Final classification => Acute myeloid leukaemia, [define by differentiation]
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: AML, NOS (ICC 2022)
        actual: AML, NOS (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - No biallelic TP53 conditions met.
        - No MDS-related genes set to True.
        - No MDS-related cytogenetics triggered classification.
        - Blasts >=20 => remain AML
        - No germline predisposition indicated (review at MDT)
        - Final => AML, NOS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLComplexScenarios::test_complex_aml_scenarios[3]
      test_class: TestAMLComplexScenarios
      test_method: test_complex_aml_scenarios
      input_data:
        blasts_percentage: 25.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation:
          ASXL1: true
          RUNX1: true
        MDS_related_cytogenetics:
          Complex_karyotype: true
          del_7q: true
        qualifiers: {}
      who_2022:
        expected: AML, myelodysplasia related (WHO 2022)
        actual: AML, myelodysplasia related (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - All AML-defining recurrent genetic abnormality flags are false.
        - 'MDS-related mutation(s): ASXL1, RUNX1 => AML, myelodysplasia related'
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML, myelodysplasia related (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: AML with myelodysplasia related gene mutation (ICC 2022)
        actual: AML with myelodysplasia related gene mutation (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 25.0'
        - 'Default classification set to: AML, NOS'
        - No ICC AML-defining abnormality is True.
        - No biallelic TP53 conditions met.
        - MDS-related genes => AML with myelodysplasia related gene mutation
        - Blasts >=20 => remain AML
        - No germline predisposition indicated (review at MDT)
        - Final => AML with myelodysplasia related gene mutation (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLComplexScenarios::test_complex_aml_scenarios[4]
      test_class: TestAMLComplexScenarios
      test_method: test_complex_aml_scenarios
      input_data:
        blasts_percentage: 30.0
        AML_defining_recurrent_genetic_abnormalities:
          NPM1: true
        MDS_related_mutation:
          ASXL1: true
          SF3B1: true
        MDS_related_cytogenetics:
          Complex_karyotype: true
        qualifiers: {}
      who_2022:
        expected: AML with NPM1 mutation (WHO 2022)
        actual: AML with NPM1 mutation (WHO 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: Acute myeloid leukaemia, [define by differentiation]'
        - 'Detected AML-defining abnormality flags: NPM1'
        - NPM1 => AML with NPM1 mutation
        - No AML_differentiation provided.
        - No germline predisposition indicated (review at MDT)
        - Final classification => AML with NPM1 mutation (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: AML with mutated NPM1 (ICC 2022)
        actual: AML with mutated NPM1 (ICC 2022)
        derivation:
        - 'Retrieved blasts_percentage: 30.0'
        - 'Default classification set to: AML, NOS'
        - ICC AML-defining flags => NPM1
        - NPM1 => AML with mutated NPM1
        - No germline predisposition indicated (review at MDT)
        - Final => AML with mutated NPM1 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestAMLErrorHandling::test_aml_invalid_blast_values[0]
      test_class: TestAMLErrorHandling
      test_method: test_aml_invalid_blast_values
      input_data: {}
      who_2022: null
      icc_2022: null
    - test_name: TestAMLErrorHandling::test_aml_invalid_blast_values[1]
      test_class: TestAMLErrorHandling
      test_method: test_aml_invalid_blast_values
      input_data: {}
      who_2022: null
      icc_2022: null
    - test_name: TestAMLErrorHandling::test_aml_invalid_blast_values[2]
      test_class: TestAMLErrorHandling
      test_method: test_aml_invalid_blast_values
      input_data: {}
      who_2022: null
      icc_2022: null
    - test_name: TestAMLErrorHandling::test_aml_invalid_blast_values[3]
      test_class: TestAMLErrorHandling
      test_method: test_aml_invalid_blast_values
      input_data: {}
      who_2022: null
      icc_2022: null
    - test_name: TestAMLErrorHandling::test_aml_invalid_blast_values[4]
      test_class: TestAMLErrorHandling
      test_method: test_aml_invalid_blast_values
      input_data: {}
      who_2022: null
      icc_2022: null
    - test_name: TestAMLErrorHandling::test_aml_invalid_blast_values[5]
      test_class: TestAMLErrorHandling
      test_method: test_aml_invalid_blast_values
      input_data: {}
      who_2022: null
      icc_2022: null
    - test_name: TestAMLErrorHandling::test_aml_robustness[0]
      test_class: TestAMLErrorHandling
      test_method: test_aml_robustness
      input_data: {}
      who_2022: null
      icc_2022: null
    - test_name: TestAMLErrorHandling::test_aml_robustness[1]
      test_class: TestAMLErrorHandling
      test_method: test_aml_robustness
      input_data:
        blasts_percentage: 25.0
      who_2022: null
      icc_2022: null
    - test_name: TestAMLErrorHandling::test_aml_robustness[2]
      test_class: TestAMLErrorHandling
      test_method: test_aml_robustness
      input_data:
        blasts_percentage: 30.0
        qualifiers: {}
      who_2022: null
      icc_2022: null
    - test_name: TestAMLErrorHandling::test_aml_robustness[3]
      test_class: TestAMLErrorHandling
      test_method: test_aml_robustness
      input_data:
        blasts_percentage: 35.0
        AML_defining_recurrent_genetic_abnormalities: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022: null
      icc_2022: null
  mds_classification:
    test_suite: MDS Classification
    timestamp: '2025-06-04T20:44:21.798165'
    total_tests: 68
    test_cases:
    - test_name: TestMDSComplexScenarios::test_complex_mds_scenarios[0]
      test_class: TestMDSComplexScenarios
      test_method: test_complex_mds_scenarios
      input_data:
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: false
          1_x_TP53_mutation_del_17p: true
          1_x_TP53_mutation_LOH: false
          1_x_TP53_mutation_50_percent_vaf: false
          1_x_TP53_mutation_10_percent_vaf: false
        blasts_percentage: 12.0
        fibrotic: false
        MDS_related_mutation:
          SF3B1: true
          ASXL1: true
          RUNX1: false
        MDS_related_cytogenetics:
          del_5q: true
          Complex_karyotype: true
        number_of_dysplastic_lineages: 3
        qualifiers:
          previous_cytotoxic_therapy: Cytotoxic chemotherapy
          predisposing_germline_variant: GATA2
      who_2022:
        expected: MDS with biallelic TP53 inactivation (WHO 2022)
        actual: MDS with biallelic TP53 inactivation (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {''2_x_TP53_mutations'': False, ''1_x_TP53_mutation_del_17p'':
          True, ''1_x_TP53_mutation_LOH'': False, ''1_x_TP53_mutation_50_percent_vaf'':
          False, ''1_x_TP53_mutation_10_percent_vaf'': False}'
        - "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - Biallelic TP53 detected => MDS with biallelic TP53 inactivation
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: MDS with mutated TP53 (ICC 2022)
        actual: MDS with mutated TP53 (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - Biallelic TP53 detected => MDS with mutated TP53
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSComplexScenarios::test_complex_mds_scenarios[1]
      test_class: TestMDSComplexScenarios
      test_method: test_complex_mds_scenarios
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 3.0
        fibrotic: false
        hypoplasia: false
        MDS_related_mutation:
          SF3B1: true
          ASXL1: false
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 2
        qualifiers:
          previous_cytotoxic_therapy: Immune interventions
          predisposing_germline_variant: RUNX1
      who_2022:
        expected: MDS with low blasts and SF3B1, associated with RUNX1 (WHO 2022)
        actual: MDS with low blasts and SF3B1, associated with RUNX1 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 3.0, fibrotic: False'
        - SF3B1 mutation detected => MDS with low blasts and SF3B1
        - Detected germline predisposition => associated with RUNX1
        - 'Classification with qualifiers: MDS with low blasts and SF3B1, associated
          with RUNX1'
        - Final classification => MDS with low blasts and SF3B1, associated with RUNX1
          (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: MDS with mutated SF3B1, therapy related, in the setting of RUNX1
          (ICC 2022)
        actual: MDS with mutated SF3B1, therapy related, in the setting of RUNX1 (ICC
          2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 3.0'
        - SF3B1 mutation detected => MDS with mutated SF3B1
        - 'Detected ICC therapy => therapy related: Immune interventions'
        - Qualifier => in the setting of RUNX1
        - Classification with qualifiers => MDS with mutated SF3B1, therapy related,
          in the setting of RUNX1
        - Final classification => MDS with mutated SF3B1, therapy related, in the
          setting of RUNX1 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSComplexScenarios::test_complex_mds_scenarios[2]
      test_class: TestMDSComplexScenarios
      test_method: test_complex_mds_scenarios
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 8.0
        fibrotic: true
        hypoplasia: false
        MDS_related_mutation:
          SF3B1: true
        MDS_related_cytogenetics:
          del_5q: true
        number_of_dysplastic_lineages: 2
        qualifiers: {}
      who_2022:
        expected: MDS, fibrotic (WHO 2022)
        actual: MDS, fibrotic (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 8.0, fibrotic: True'
        - 5-9% blasts => MDS with increased blasts 1
        - Blasts 5-19% with fibrotic marrow => MDS, fibrotic
        - 'Current classification: MDS, fibrotic'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, fibrotic (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: MDS with excess blasts (ICC 2022)
        actual: MDS with excess blasts (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 8.0'
        - 5-9% blasts => MDS with excess blasts
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with excess blasts (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSComplexScenarios::test_complex_mds_scenarios[3]
      test_class: TestMDSComplexScenarios
      test_method: test_complex_mds_scenarios
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 2.0
        fibrotic: false
        hypoplasia: true
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 1
        qualifiers:
          predisposing_germline_variant: ANKRD26 (thrombocytopenia 2)
      who_2022:
        expected: MDS, hypoplastic, associated with ANKRD26 (WHO 2022)
        actual: MDS, hypoplastic, associated with ANKRD26 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 2.0, fibrotic: False'
        - Hypoplasia detected => MDS, hypoplastic
        - Detected germline predisposition => associated with ANKRD26
        - 'Classification with qualifiers: MDS, hypoplastic, associated with ANKRD26'
        - Final classification => MDS, hypoplastic, associated with ANKRD26 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: MDS, NOS with single lineage dysplasia, in the setting of ANKRD26
          (ICC 2022)
        actual: MDS, NOS with single lineage dysplasia, in the setting of ANKRD26
          (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 2.0'
        - 'number_of_dysplastic_lineages: 1'
        - Single lineage dysplasia => MDS, NOS with single lineage dysplasia
        - Qualifier => in the setting of ANKRD26
        - Classification with qualifiers => MDS, NOS with single lineage dysplasia,
          in the setting of ANKRD26
        - Final classification => MDS, NOS with single lineage dysplasia, in the setting
          of ANKRD26 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSComplexScenarios::test_complex_mds_scenarios[4]
      test_class: TestMDSComplexScenarios
      test_method: test_complex_mds_scenarios
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 4.0
        number_of_dysplastic_lineages: 2
        qualifiers:
          predisposing_germline_variant: Diamond-Blackfan anemia, germline BLM mutation,
            GATA2
      who_2022:
        expected: MDS with low blasts, associated with germline BLM mutation, GATA2
          (WHO 2022)
        actual: MDS with low blasts, associated with germline BLM mutation, GATA2
          (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 4.0, fibrotic: False'
        - Multiple dysplastic lineages => MDS with low blasts
        - Detected germline predisposition => associated with germline BLM mutation,
          GATA2
        - 'Classification with qualifiers: MDS with low blasts, associated with germline
          BLM mutation, GATA2'
        - Final classification => MDS with low blasts, associated with germline BLM
          mutation, GATA2 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022:
        expected: MDS, NOS with multilineage dysplasia, in the setting of Diamond-Blackfan
          anemia, GATA2 (ICC 2022)
        actual: MDS, NOS with multilineage dysplasia, in the setting of Diamond-Blackfan
          anemia, GATA2 (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 4.0'
        - 'number_of_dysplastic_lineages: 2'
        - Multilineage dysplasia => MDS, NOS with multilineage dysplasia
        - Qualifier => in the setting of Diamond-Blackfan anemia, GATA2
        - Classification with qualifiers => MDS, NOS with multilineage dysplasia,
          in the setting of Diamond-Blackfan anemia, GATA2
        - Final classification => MDS, NOS with multilineage dysplasia, in the setting
          of Diamond-Blackfan anemia, GATA2 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSErrorHandling::test_mds_robustness[0]
      test_class: TestMDSErrorHandling
      test_method: test_mds_robustness
      input_data: {}
      who_2022: null
      icc_2022: null
    - test_name: TestMDSErrorHandling::test_mds_robustness[1]
      test_class: TestMDSErrorHandling
      test_method: test_mds_robustness
      input_data:
        blasts_percentage: 5.0
      who_2022: null
      icc_2022: null
    - test_name: TestMDSErrorHandling::test_mds_robustness[2]
      test_class: TestMDSErrorHandling
      test_method: test_mds_robustness
      input_data:
        blasts_percentage: 10.0
        qualifiers: {}
      who_2022: null
      icc_2022: null
    - test_name: TestMDSErrorHandling::test_mds_robustness[3]
      test_class: TestMDSErrorHandling
      test_method: test_mds_robustness
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 7.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022: null
      icc_2022: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[0]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: true
          1_x_TP53_mutation_del_17p: false
          1_x_TP53_mutation_LOH: false
          1_x_TP53_mutation_50_percent_vaf: false
          1_x_TP53_mutation_10_percent_vaf: false
        blasts_percentage: 8.0
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS with mutated TP53 (ICC 2022)
        actual: MDS with mutated TP53 (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - Biallelic TP53 detected => MDS with mutated TP53
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[1]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: false
          1_x_TP53_mutation_del_17p: true
          1_x_TP53_mutation_LOH: false
          1_x_TP53_mutation_50_percent_vaf: false
          1_x_TP53_mutation_10_percent_vaf: false
        blasts_percentage: 12.0
      who_2022: null
      icc_2022:
        expected: MDS with mutated TP53 (ICC 2022)
        actual: MDS with mutated TP53 (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - Biallelic TP53 detected => MDS with mutated TP53
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[2]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 7.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 2
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS with excess blasts (ICC 2022)
        actual: MDS with excess blasts (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 7.0'
        - 5-9% blasts => MDS with excess blasts
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with excess blasts (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[3]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 14.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 1
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS/AML (ICC 2022)
        actual: MDS/AML (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 14.0'
        - 10-19% blasts => MDS/AML
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS/AML (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[4]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 2.0
        MDS_related_mutation:
          SF3B1: true
          ASXL1: false
          RUNX1: false
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS with mutated SF3B1 (ICC 2022)
        actual: MDS with mutated SF3B1 (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 2.0'
        - SF3B1 mutation detected => MDS with mutated SF3B1
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with mutated SF3B1 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[5]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 3.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics:
          del_5q: true
          complex_karyotype: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS with del(5q) (ICC 2022)
        actual: MDS with del(5q) (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 3.0'
        - del(5q) detected => MDS with del(5q)
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with del(5q) (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[6]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 2.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 1
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS, NOS with single lineage dysplasia (ICC 2022)
        actual: MDS, NOS with single lineage dysplasia (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 2.0'
        - 'number_of_dysplastic_lineages: 1'
        - Single lineage dysplasia => MDS, NOS with single lineage dysplasia
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, NOS with single lineage dysplasia (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[7]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 4.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 3
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS, NOS with multilineage dysplasia (ICC 2022)
        actual: MDS, NOS with multilineage dysplasia (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 4.0'
        - 'number_of_dysplastic_lineages: 3'
        - Multilineage dysplasia => MDS, NOS with multilineage dysplasia
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, NOS with multilineage dysplasia (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[8]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 1.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics:
          monosomy_7: true
          complex_karyotype: false
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS, NOS without dysplasia (ICC 2022)
        actual: MDS, NOS without dysplasia (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 1.0'
        - 'number_of_dysplastic_lineages: None'
        - Monosomy 7 or complex karyotype detected => MDS, NOS without dysplasia
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, NOS without dysplasia (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[9]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 2.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics:
          monosomy_7: false
          complex_karyotype: true
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS, NOS without dysplasia (ICC 2022)
        actual: MDS, NOS without dysplasia (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 2.0'
        - 'number_of_dysplastic_lineages: None'
        - Monosomy 7 or complex karyotype detected => MDS, NOS without dysplasia
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, NOS without dysplasia (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_basic_mds_icc2022_classification[10]
      test_class: TestMDSICC2022Classification
      test_method: test_basic_mds_icc2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 1.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS, NOS (ICC 2022)
        actual: MDS, NOS (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 1.0'
        - 'number_of_dysplastic_lineages: None'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, NOS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_edge_cases[0]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS, NOS (ICC 2022)
        actual: MDS, NOS (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: None'
        - 'number_of_dysplastic_lineages: None'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, NOS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_edge_cases[1]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_edge_cases
      input_data:
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: true
          1_x_TP53_mutation_del_17p: true
          1_x_TP53_mutation_LOH: true
        blasts_percentage: 10.0
      who_2022: null
      icc_2022:
        expected: MDS with mutated TP53 (ICC 2022)
        actual: MDS with mutated TP53 (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: True, with del17p: True, with LOH: True,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - Biallelic TP53 detected => MDS with mutated TP53
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_edge_cases[2]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 5.0
        number_of_dysplastic_lineages: 1
      who_2022: null
      icc_2022:
        expected: MDS with excess blasts (ICC 2022)
        actual: MDS with excess blasts (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 5.0'
        - 5-9% blasts => MDS with excess blasts
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with excess blasts (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_edge_cases[3]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 9.0
        number_of_dysplastic_lineages: 1
      who_2022: null
      icc_2022:
        expected: MDS with excess blasts (ICC 2022)
        actual: MDS with excess blasts (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 9.0'
        - 5-9% blasts => MDS with excess blasts
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with excess blasts (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_edge_cases[4]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 10.0
        number_of_dysplastic_lineages: 1
      who_2022: null
      icc_2022:
        expected: MDS/AML (ICC 2022)
        actual: MDS/AML (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 10.0'
        - 10-19% blasts => MDS/AML
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS/AML (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_edge_cases[5]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 19.0
        number_of_dysplastic_lineages: 1
      who_2022: null
      icc_2022:
        expected: MDS/AML (ICC 2022)
        actual: MDS/AML (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 19.0'
        - 10-19% blasts => MDS/AML
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS/AML (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_edge_cases[6]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 2.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 0
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS, NOS (ICC 2022)
        actual: MDS, NOS (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 2.0'
        - 'number_of_dysplastic_lineages: 0'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, NOS (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_edge_cases[7]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 1.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics:
          monosomy_7: true
          complex_karyotype: true
        qualifiers: {}
      who_2022: null
      icc_2022:
        expected: MDS, NOS without dysplasia (ICC 2022)
        actual: MDS, NOS without dysplasia (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 1.0'
        - 'number_of_dysplastic_lineages: None'
        - Monosomy 7 or complex karyotype detected => MDS, NOS without dysplasia
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, NOS without dysplasia (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_with_qualifiers[0]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 6.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 2
        qualifiers:
          previous_cytotoxic_therapy: Ionising radiation
      who_2022: null
      icc_2022:
        expected: MDS with excess blasts, therapy related (ICC 2022)
        actual: MDS with excess blasts, therapy related (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 6.0'
        - 5-9% blasts => MDS with excess blasts
        - 'Detected ICC therapy => therapy related: Ionising radiation'
        - No germline predisposition indicated (review at MDT)
        - Classification with qualifiers => MDS with excess blasts, therapy related
        - Final classification => MDS with excess blasts, therapy related (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_with_qualifiers[1]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 13.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 1
        qualifiers:
          previous_cytotoxic_therapy: Cytotoxic chemotherapy
      who_2022: null
      icc_2022:
        expected: MDS/AML, therapy related (ICC 2022)
        actual: MDS/AML, therapy related (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 13.0'
        - 10-19% blasts => MDS/AML
        - 'Detected ICC therapy => therapy related: Cytotoxic chemotherapy'
        - No germline predisposition indicated (review at MDT)
        - Classification with qualifiers => MDS/AML, therapy related
        - Final classification => MDS/AML, therapy related (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_with_qualifiers[2]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 2.0
        MDS_related_mutation:
          SF3B1: true
        MDS_related_cytogenetics: {}
        qualifiers:
          previous_cytotoxic_therapy: Immune interventions
      who_2022: null
      icc_2022:
        expected: MDS with mutated SF3B1, therapy related (ICC 2022)
        actual: MDS with mutated SF3B1, therapy related (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 2.0'
        - SF3B1 mutation detected => MDS with mutated SF3B1
        - 'Detected ICC therapy => therapy related: Immune interventions'
        - No germline predisposition indicated (review at MDT)
        - Classification with qualifiers => MDS with mutated SF3B1, therapy related
        - Final classification => MDS with mutated SF3B1, therapy related (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_with_qualifiers[3]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 3.0
        MDS_related_cytogenetics:
          del_5q: true
        qualifiers:
          previous_cytotoxic_therapy: Any combination
      who_2022: null
      icc_2022:
        expected: MDS with del(5q), therapy related (ICC 2022)
        actual: MDS with del(5q), therapy related (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 3.0'
        - del(5q) detected => MDS with del(5q)
        - 'Detected ICC therapy => therapy related: Any combination'
        - No germline predisposition indicated (review at MDT)
        - Classification with qualifiers => MDS with del(5q), therapy related
        - Final classification => MDS with del(5q), therapy related (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_with_qualifiers[4]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 8.0
        number_of_dysplastic_lineages: 1
        qualifiers:
          predisposing_germline_variant: RUNX1
      who_2022: null
      icc_2022:
        expected: MDS with excess blasts, in the setting of RUNX1 (ICC 2022)
        actual: MDS with excess blasts, in the setting of RUNX1 (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 8.0'
        - 5-9% blasts => MDS with excess blasts
        - Qualifier => in the setting of RUNX1
        - Classification with qualifiers => MDS with excess blasts, in the setting
          of RUNX1
        - Final classification => MDS with excess blasts, in the setting of RUNX1
          (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_with_qualifiers[5]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 12.0
        qualifiers:
          predisposing_germline_variant: GATA2, DDX41
      who_2022: null
      icc_2022:
        expected: MDS/AML, in the setting of GATA2, DDX41 (ICC 2022)
        actual: MDS/AML, in the setting of GATA2, DDX41 (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 12.0'
        - 10-19% blasts => MDS/AML
        - Qualifier => in the setting of GATA2, DDX41
        - Classification with qualifiers => MDS/AML, in the setting of GATA2, DDX41
        - Final classification => MDS/AML, in the setting of GATA2, DDX41 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_with_qualifiers[6]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 4.0
        number_of_dysplastic_lineages: 1
        qualifiers:
          predisposing_germline_variant: germline BLM mutation
      who_2022: null
      icc_2022:
        expected: MDS, NOS with single lineage dysplasia (ICC 2022)
        actual: MDS, NOS with single lineage dysplasia (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 4.0'
        - 'number_of_dysplastic_lineages: 1'
        - Single lineage dysplasia => MDS, NOS with single lineage dysplasia
        - Final classification => MDS, NOS with single lineage dysplasia (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_with_qualifiers[7]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 9.0
        number_of_dysplastic_lineages: 2
        qualifiers:
          previous_cytotoxic_therapy: Cytotoxic chemotherapy
          predisposing_germline_variant: GATA2
      who_2022: null
      icc_2022:
        expected: MDS with excess blasts, therapy related, in the setting of GATA2
          (ICC 2022)
        actual: MDS with excess blasts, therapy related, in the setting of GATA2 (ICC
          2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 9.0'
        - 5-9% blasts => MDS with excess blasts
        - 'Detected ICC therapy => therapy related: Cytotoxic chemotherapy'
        - Qualifier => in the setting of GATA2
        - Classification with qualifiers => MDS with excess blasts, therapy related,
          in the setting of GATA2
        - Final classification => MDS with excess blasts, therapy related, in the
          setting of GATA2 (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSICC2022Classification::test_mds_icc2022_with_qualifiers[8]
      test_class: TestMDSICC2022Classification
      test_method: test_mds_icc2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 1.0
        MDS_related_cytogenetics:
          monosomy_7: true
        qualifiers:
          predisposing_germline_variant: RUNX1 (familial platelet disorder)
      who_2022: null
      icc_2022:
        expected: MDS, NOS without dysplasia, in the setting of RUNX1 (ICC 2022)
        actual: MDS, NOS without dysplasia, in the setting of RUNX1 (ICC 2022)
        derivation:
        - 'Default classification set to: MDS, NOS'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'blasts_percentage: 1.0'
        - 'number_of_dysplastic_lineages: None'
        - Monosomy 7 or complex karyotype detected => MDS, NOS without dysplasia
        - Qualifier => in the setting of RUNX1
        - Classification with qualifiers => MDS, NOS without dysplasia, in the setting
          of RUNX1
        - Final classification => MDS, NOS without dysplasia, in the setting of RUNX1
          (ICC 2022)
        success: true
        matches_expected: true
        error: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[0]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: true
          1_x_TP53_mutation_del_17p: false
          1_x_TP53_mutation_LOH: false
          1_x_TP53_mutation_50_percent_vaf: false
          1_x_TP53_mutation_10_percent_vaf: false
        blasts_percentage: 8.0
        qualifiers: {}
      who_2022:
        expected: MDS with biallelic TP53 inactivation (WHO 2022)
        actual: MDS with biallelic TP53 inactivation (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {''2_x_TP53_mutations'': True, ''1_x_TP53_mutation_del_17p'':
          False, ''1_x_TP53_mutation_LOH'': False, ''1_x_TP53_mutation_50_percent_vaf'':
          False, ''1_x_TP53_mutation_10_percent_vaf'': False}'
        - "TP53 conditions: 2 mutations: True, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - Biallelic TP53 detected => MDS with biallelic TP53 inactivation
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[1]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: false
          1_x_TP53_mutation_del_17p: true
          1_x_TP53_mutation_LOH: false
          1_x_TP53_mutation_50_percent_vaf: false
          1_x_TP53_mutation_10_percent_vaf: false
        blasts_percentage: 12.0
      who_2022:
        expected: MDS with biallelic TP53 inactivation (WHO 2022)
        actual: MDS with biallelic TP53 inactivation (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {''2_x_TP53_mutations'': False, ''1_x_TP53_mutation_del_17p'':
          True, ''1_x_TP53_mutation_LOH'': False, ''1_x_TP53_mutation_50_percent_vaf'':
          False, ''1_x_TP53_mutation_10_percent_vaf'': False}'
        - "TP53 conditions: 2 mutations: False, with del17p: True, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - Biallelic TP53 detected => MDS with biallelic TP53 inactivation
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[2]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: false
          1_x_TP53_mutation_del_17p: false
          1_x_TP53_mutation_LOH: true
          1_x_TP53_mutation_50_percent_vaf: false
          1_x_TP53_mutation_10_percent_vaf: false
        blasts_percentage: 5.0
      who_2022:
        expected: MDS with biallelic TP53 inactivation (WHO 2022)
        actual: MDS with biallelic TP53 inactivation (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {''2_x_TP53_mutations'': False, ''1_x_TP53_mutation_del_17p'':
          False, ''1_x_TP53_mutation_LOH'': True, ''1_x_TP53_mutation_50_percent_vaf'':
          False, ''1_x_TP53_mutation_10_percent_vaf'': False}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: True,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - Biallelic TP53 detected => MDS with biallelic TP53 inactivation
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[3]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: false
          1_x_TP53_mutation_del_17p: false
          1_x_TP53_mutation_LOH: false
          1_x_TP53_mutation_50_percent_vaf: true
          1_x_TP53_mutation_10_percent_vaf: false
        blasts_percentage: 15.0
      who_2022:
        expected: MDS with biallelic TP53 inactivation (WHO 2022)
        actual: MDS with biallelic TP53 inactivation (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {''2_x_TP53_mutations'': False, ''1_x_TP53_mutation_del_17p'':
          False, ''1_x_TP53_mutation_LOH'': False, ''1_x_TP53_mutation_50_percent_vaf'':
          True, ''1_x_TP53_mutation_10_percent_vaf'': False}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: True, with \u226510% VAF + complex karyotype: False"
        - Biallelic TP53 detected => MDS with biallelic TP53 inactivation
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[4]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: false
          1_x_TP53_mutation_del_17p: false
          1_x_TP53_mutation_LOH: false
          1_x_TP53_mutation_50_percent_vaf: false
          1_x_TP53_mutation_10_percent_vaf: true
        MDS_related_cytogenetics:
          Complex_karyotype: true
        blasts_percentage: 3.0
      who_2022:
        expected: MDS with biallelic TP53 inactivation (WHO 2022)
        actual: MDS with biallelic TP53 inactivation (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {''2_x_TP53_mutations'': False, ''1_x_TP53_mutation_del_17p'':
          False, ''1_x_TP53_mutation_LOH'': False, ''1_x_TP53_mutation_50_percent_vaf'':
          False, ''1_x_TP53_mutation_10_percent_vaf'': True}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: True"
        - Biallelic TP53 detected => MDS with biallelic TP53 inactivation
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[5]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 7.0
        fibrotic: false
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 2
        qualifiers: {}
      who_2022:
        expected: MDS with increased blasts 1 (WHO 2022)
        actual: MDS with increased blasts 1 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 7.0, fibrotic: False'
        - 5-9% blasts => MDS with increased blasts 1
        - 'Current classification: MDS with increased blasts 1'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with increased blasts 1 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[6]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 14.0
        fibrotic: false
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 1
        qualifiers: {}
      who_2022:
        expected: MDS with increased blasts 2 (WHO 2022)
        actual: MDS with increased blasts 2 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 14.0, fibrotic: False'
        - 10-19% blasts => MDS with increased blasts 2
        - 'Current classification: MDS with increased blasts 2'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with increased blasts 2 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[7]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 8.0
        fibrotic: true
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022:
        expected: MDS, fibrotic (WHO 2022)
        actual: MDS, fibrotic (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 8.0, fibrotic: True'
        - 5-9% blasts => MDS with increased blasts 1
        - Blasts 5-19% with fibrotic marrow => MDS, fibrotic
        - 'Current classification: MDS, fibrotic'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, fibrotic (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[8]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 2.0
        fibrotic: false
        MDS_related_mutation:
          SF3B1: true
          ASXL1: false
          RUNX1: false
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022:
        expected: MDS with low blasts and SF3B1 (WHO 2022)
        actual: MDS with low blasts and SF3B1 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 2.0, fibrotic: False'
        - SF3B1 mutation detected => MDS with low blasts and SF3B1
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with low blasts and SF3B1 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[9]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 3.0
        fibrotic: false
        MDS_related_mutation: {}
        MDS_related_cytogenetics:
          del_5q: true
          Complex_karyotype: false
        qualifiers: {}
      who_2022:
        expected: MDS with low blasts and isolated 5q- (WHO 2022)
        actual: MDS with low blasts and isolated 5q- (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 3.0, fibrotic: False'
        - del(5q) detected => MDS with low blasts and isolated 5q-
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with low blasts and isolated 5q- (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[10]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 1.0
        hypoplasia: true
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022:
        expected: MDS, hypoplastic (WHO 2022)
        actual: MDS, hypoplastic (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 1.0, fibrotic: False'
        - Hypoplasia detected => MDS, hypoplastic
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, hypoplastic (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[11]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 2.0
        fibrotic: false
        hypoplasia: false
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 1
        qualifiers: {}
      who_2022:
        expected: MDS with low blasts (WHO 2022)
        actual: MDS with low blasts (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 2.0, fibrotic: False'
        - Single dysplastic lineage => MDS with low blasts
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with low blasts (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[12]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 4.0
        fibrotic: false
        hypoplasia: false
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 3
        qualifiers: {}
      who_2022:
        expected: MDS with low blasts (WHO 2022)
        actual: MDS with low blasts (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 4.0, fibrotic: False'
        - Multiple dysplastic lineages => MDS with low blasts
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with low blasts (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_basic_mds_who2022_classification[13]
      test_class: TestMDSWHO2022Classification
      test_method: test_basic_mds_who2022_classification
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 1.0
        fibrotic: false
        hypoplasia: false
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022:
        expected: MDS, unclassifiable (WHO 2022)
        actual: MDS, unclassifiable (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 1.0, fibrotic: False'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, unclassifiable (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_edge_cases[0]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        qualifiers: {}
      who_2022:
        expected: MDS, unclassifiable (WHO 2022)
        actual: MDS, unclassifiable (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: None, fibrotic: False'
        - No blasts_percentage provided; skipping blast-based classification.
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, unclassifiable (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_edge_cases[1]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_edge_cases
      input_data:
        Biallelic_TP53_mutation:
          2_x_TP53_mutations: true
          1_x_TP53_mutation_del_17p: true
          1_x_TP53_mutation_LOH: true
        blasts_percentage: 10.0
      who_2022:
        expected: MDS with biallelic TP53 inactivation (WHO 2022)
        actual: MDS with biallelic TP53 inactivation (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {''2_x_TP53_mutations'': True, ''1_x_TP53_mutation_del_17p'':
          True, ''1_x_TP53_mutation_LOH'': True}'
        - "TP53 conditions: 2 mutations: True, with del17p: True, with LOH: True,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - Biallelic TP53 detected => MDS with biallelic TP53 inactivation
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_edge_cases[2]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 5.0
        fibrotic: false
        number_of_dysplastic_lineages: 1
      who_2022:
        expected: MDS with increased blasts 1 (WHO 2022)
        actual: MDS with increased blasts 1 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 5.0, fibrotic: False'
        - 5-9% blasts => MDS with increased blasts 1
        - 'Current classification: MDS with increased blasts 1'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with increased blasts 1 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_edge_cases[3]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 9.0
        fibrotic: false
        number_of_dysplastic_lineages: 1
      who_2022:
        expected: MDS with increased blasts 1 (WHO 2022)
        actual: MDS with increased blasts 1 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 9.0, fibrotic: False'
        - 5-9% blasts => MDS with increased blasts 1
        - 'Current classification: MDS with increased blasts 1'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with increased blasts 1 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_edge_cases[4]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 10.0
        fibrotic: false
        number_of_dysplastic_lineages: 1
      who_2022:
        expected: MDS with increased blasts 2 (WHO 2022)
        actual: MDS with increased blasts 2 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 10.0, fibrotic: False'
        - 10-19% blasts => MDS with increased blasts 2
        - 'Current classification: MDS with increased blasts 2'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with increased blasts 2 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_edge_cases[5]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 19.0
        fibrotic: false
        number_of_dysplastic_lineages: 1
      who_2022:
        expected: MDS with increased blasts 2 (WHO 2022)
        actual: MDS with increased blasts 2 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 19.0, fibrotic: False'
        - 10-19% blasts => MDS with increased blasts 2
        - 'Current classification: MDS with increased blasts 2'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS with increased blasts 2 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_edge_cases[6]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 5.0
        fibrotic: true
      who_2022:
        expected: MDS, fibrotic (WHO 2022)
        actual: MDS, fibrotic (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 5.0, fibrotic: True'
        - 5-9% blasts => MDS with increased blasts 1
        - Blasts 5-19% with fibrotic marrow => MDS, fibrotic
        - 'Current classification: MDS, fibrotic'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, fibrotic (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_edge_cases[7]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_edge_cases
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 19.0
        fibrotic: true
      who_2022:
        expected: MDS, fibrotic (WHO 2022)
        actual: MDS, fibrotic (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 19.0, fibrotic: True'
        - 10-19% blasts => MDS with increased blasts 2
        - Blasts 5-19% with fibrotic marrow => MDS, fibrotic
        - 'Current classification: MDS, fibrotic'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, fibrotic (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_with_qualifiers[0]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 6.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 2
        qualifiers:
          previous_cytotoxic_therapy: Ionising radiation
      who_2022:
        expected: MDS with increased blasts 1, previous cytotoxic therapy (WHO 2022)
        actual: MDS with increased blasts 1, previous cytotoxic therapy (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 6.0, fibrotic: False'
        - 5-9% blasts => MDS with increased blasts 1
        - 'Current classification: MDS with increased blasts 1'
        - 'Detected WHO therapy => previous cytotoxic therapy: Ionising radiation'
        - No germline predisposition indicated (review at MDT)
        - 'Classification with qualifiers: MDS with increased blasts 1, previous cytotoxic
          therapy'
        - Final classification => MDS with increased blasts 1, previous cytotoxic
          therapy (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_with_qualifiers[1]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 13.0
        MDS_related_mutation: {}
        MDS_related_cytogenetics: {}
        number_of_dysplastic_lineages: 1
        qualifiers:
          previous_cytotoxic_therapy: Cytotoxic chemotherapy
      who_2022:
        expected: MDS with increased blasts 2, previous cytotoxic therapy (WHO 2022)
        actual: MDS with increased blasts 2, previous cytotoxic therapy (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 13.0, fibrotic: False'
        - 10-19% blasts => MDS with increased blasts 2
        - 'Current classification: MDS with increased blasts 2'
        - 'Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy'
        - No germline predisposition indicated (review at MDT)
        - 'Classification with qualifiers: MDS with increased blasts 2, previous cytotoxic
          therapy'
        - Final classification => MDS with increased blasts 2, previous cytotoxic
          therapy (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_with_qualifiers[2]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 2.0
        MDS_related_mutation:
          SF3B1: true
        MDS_related_cytogenetics: {}
        qualifiers:
          previous_cytotoxic_therapy: Any combination
      who_2022:
        expected: MDS with low blasts and SF3B1, previous cytotoxic therapy (WHO 2022)
        actual: MDS with low blasts and SF3B1, previous cytotoxic therapy (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 2.0, fibrotic: False'
        - SF3B1 mutation detected => MDS with low blasts and SF3B1
        - 'Detected WHO therapy => previous cytotoxic therapy: Any combination'
        - No germline predisposition indicated (review at MDT)
        - 'Classification with qualifiers: MDS with low blasts and SF3B1, previous
          cytotoxic therapy'
        - Final classification => MDS with low blasts and SF3B1, previous cytotoxic
          therapy (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_with_qualifiers[3]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 8.0
        fibrotic: true
        qualifiers:
          previous_cytotoxic_therapy: Immune interventions
      who_2022:
        expected: MDS, fibrotic (WHO 2022)
        actual: MDS, fibrotic (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 8.0, fibrotic: True'
        - 5-9% blasts => MDS with increased blasts 1
        - Blasts 5-19% with fibrotic marrow => MDS, fibrotic
        - 'Current classification: MDS, fibrotic'
        - No germline predisposition indicated (review at MDT)
        - Final classification => MDS, fibrotic (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_with_qualifiers[4]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 3.0
        MDS_related_cytogenetics:
          del_5q: true
        qualifiers:
          predisposing_germline_variant: RUNX1
      who_2022:
        expected: MDS with low blasts and isolated 5q-, associated with RUNX1 (WHO
          2022)
        actual: MDS with low blasts and isolated 5q-, associated with RUNX1 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 3.0, fibrotic: False'
        - del(5q) detected => MDS with low blasts and isolated 5q-
        - Detected germline predisposition => associated with RUNX1
        - 'Classification with qualifiers: MDS with low blasts and isolated 5q-, associated
          with RUNX1'
        - Final classification => MDS with low blasts and isolated 5q-, associated
          with RUNX1 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_with_qualifiers[5]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 12.0
        qualifiers:
          predisposing_germline_variant: GATA2, DDX41
      who_2022:
        expected: MDS with increased blasts 2, associated with GATA2, DDX41 (WHO 2022)
        actual: MDS with increased blasts 2, associated with GATA2, DDX41 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 12.0, fibrotic: False'
        - 10-19% blasts => MDS with increased blasts 2
        - 'Current classification: MDS with increased blasts 2'
        - Detected germline predisposition => associated with GATA2, DDX41
        - 'Classification with qualifiers: MDS with increased blasts 2, associated
          with GATA2, DDX41'
        - Final classification => MDS with increased blasts 2, associated with GATA2,
          DDX41 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_with_qualifiers[6]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 4.0
        number_of_dysplastic_lineages: 1
        qualifiers:
          predisposing_germline_variant: Diamond-Blackfan anemia
      who_2022:
        expected: MDS with low blasts (WHO 2022)
        actual: MDS with low blasts (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 4.0, fibrotic: False'
        - Single dysplastic lineage => MDS with low blasts
        - Final classification => MDS with low blasts (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_with_qualifiers[7]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 9.0
        number_of_dysplastic_lineages: 2
        qualifiers:
          previous_cytotoxic_therapy: Cytotoxic chemotherapy
          predisposing_germline_variant: GATA2
      who_2022:
        expected: MDS with increased blasts 1, previous cytotoxic therapy, associated
          with GATA2 (WHO 2022)
        actual: MDS with increased blasts 1, previous cytotoxic therapy, associated
          with GATA2 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 9.0, fibrotic: False'
        - 5-9% blasts => MDS with increased blasts 1
        - 'Current classification: MDS with increased blasts 1'
        - 'Detected WHO therapy => previous cytotoxic therapy: Cytotoxic chemotherapy'
        - Detected germline predisposition => associated with GATA2
        - 'Classification with qualifiers: MDS with increased blasts 1, previous cytotoxic
          therapy, associated with GATA2'
        - Final classification => MDS with increased blasts 1, previous cytotoxic
          therapy, associated with GATA2 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
    - test_name: TestMDSWHO2022Classification::test_mds_who2022_with_qualifiers[8]
      test_class: TestMDSWHO2022Classification
      test_method: test_mds_who2022_with_qualifiers
      input_data:
        Biallelic_TP53_mutation: {}
        blasts_percentage: 2.0
        hypoplasia: true
        qualifiers:
          predisposing_germline_variant: RUNX1 (familial platelet disorder)
      who_2022:
        expected: MDS, hypoplastic, associated with RUNX1 (WHO 2022)
        actual: MDS, hypoplastic, associated with RUNX1 (WHO 2022)
        derivation:
        - 'Default classification set to: MDS, unclassifiable'
        - 'Checking for biallelic TP53: {}'
        - "TP53 conditions: 2 mutations: False, with del17p: False, with LOH: False,\
          \ with \u226550% VAF: False, with \u226510% VAF + complex karyotype: False"
        - 'Retrieved blasts: 2.0, fibrotic: False'
        - Hypoplasia detected => MDS, hypoplastic
        - Detected germline predisposition => associated with RUNX1
        - 'Classification with qualifiers: MDS, hypoplastic, associated with RUNX1'
        - Final classification => MDS, hypoplastic, associated with RUNX1 (WHO 2022)
        success: true
        matches_expected: true
        error: null
      icc_2022: null
summary:
  aml:
    total_tests: 102
    who_2022_passed: 55
    icc_2022_passed: 50
    who_2022_errors: 0
    icc_2022_errors: 0
    who_2022_total: 55
    icc_2022_total: 50
  mds:
    total_tests: 68
    who_2022_passed: 36
    icc_2022_passed: 33
    who_2022_errors: 0
    icc_2022_errors: 0
    who_2022_total: 36
    icc_2022_total: 33
